News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
174,782 Results
Type
Article (12877)
Company Profile (23)
Press Release (161882)
Multimedia
Podcasts (9)
Webinars (5)
Section
Business (48450)
Career Advice (610)
Deals (9065)
Drug Delivery (30)
Drug Development (27924)
Employer Resources (69)
FDA (4662)
Job Trends (3845)
News (90716)
Policy (7799)
Tag
2024 BioMidwest Digital (2)
2024 Bio NC Digital (1)
2024 Biotech Bay Standard (4)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (2)
2024 Pharm Country Standard (2)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (1072)
Academic (1)
Accelerated approval (1)
Adcomms (6)
Allergies (31)
Alliances (13637)
ALS (37)
Alzheimer's disease (432)
Antibody-drug conjugate (ADC) (22)
Approvals (4673)
Artificial intelligence (58)
Autoimmune disease (8)
Automation (3)
Bankruptcy (70)
Best Places to Work (3195)
BIOSECURE Act (6)
Biosimilars (34)
Biotechnology (11)
Bladder cancer (20)
Brain cancer (8)
Breast cancer (79)
Cancer (551)
Cardiovascular disease (60)
Career advice (512)
Career pathing (13)
CAR-T (45)
Cell therapy (107)
Cervical cancer (9)
Clinical research (23737)
Collaboration (165)
Compensation (14)
Complete response letters (1)
COVID-19 (1077)
CRISPR (8)
C-suite (52)
Cystic fibrosis (20)
Data (699)
Denatured (6)
Depression (8)
Diabetes (92)
Diagnostics (1693)
Digital health (3)
Diversity (5)
Diversity, equity & inclusion (28)
Drug discovery (37)
Drug pricing (38)
Drug shortages (16)
Duchenne muscular dystrophy (31)
Earnings (14224)
Editorial (16)
Employer branding (5)
Employer resources (63)
Events (20746)
Executive appointments (182)
FDA (4981)
Featured Employer (10)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (194)
Gene editing (17)
Generative AI (6)
Gene therapy (81)
GLP-1 (265)
Government (1173)
Grass and pollen (1)
Guidances (10)
Healthcare (5370)
Huntington's disease (6)
IgA nephropathy (9)
Immunology and inflammation (30)
Indications (6)
Infectious disease (1121)
Inflammatory bowel disease (52)
Inflation Reduction Act (4)
Influenza (14)
Intellectual property (16)
Interviews (104)
IPO (3421)
IRA (19)
Job creations (773)
Job search strategy (450)
Kidney cancer (2)
Labor market (6)
Layoffs (77)
Leadership (7)
Legal (1521)
Liver cancer (21)
Lung cancer (61)
Lymphoma (41)
Machine learning (1)
Management (22)
Manufacturing (66)
MASH (32)
Medical device (3157)
Medtech (3159)
Mergers & acquisitions (5787)
Metabolic disorders (210)
Multiple sclerosis (38)
NASH (15)
Neurodegenerative disease (21)
Neuropsychiatric disorders (3)
Neuroscience (607)
NextGen: Class of 2025 (1994)
Non-profit (1632)
Northern California (502)
Obesity (96)
Opinion (46)
Ovarian cancer (15)
Pain (31)
Pancreatic cancer (20)
Parkinson's disease (54)
Partnered (7)
Patents (28)
Patient recruitment (33)
Peanut (17)
People (17240)
Pharmaceutical (11)
Pharmacy benefit managers (9)
Phase I (5264)
Phase II (10200)
Phase III (9677)
Pipeline (281)
Policy (53)
Postmarket research (1147)
Preclinical (1896)
Press Release (29)
Prostate cancer (34)
Psychedelics (9)
Radiopharmaceuticals (62)
Rare diseases (106)
Real estate (1372)
Recruiting (23)
Regulatory (5713)
Reports (13)
Research institute (891)
Resumes & cover letters (82)
Rett syndrome (1)
RSV (18)
Schizophrenia (22)
Series A (46)
Series B (29)
Service/supplier (2)
Sickle cell disease (12)
Southern California (483)
Special edition (2)
Spinal muscular atrophy (62)
Sponsored (4)
Startups (1178)
Stomach cancer (4)
Supply chain (15)
Tariffs (6)
The Weekly (3)
United States (4708)
Vaccines (277)
Venture capitalists (8)
Weight loss (69)
Women's health (14)
Worklife (6)
Date
Today (6)
Last 7 days (103)
Last 30 days (572)
Last 365 days (7974)
2025 (2259)
2024 (8396)
2023 (9575)
2022 (12861)
2021 (14425)
2020 (14005)
2019 (13487)
2018 (10423)
2017 (9482)
2016 (9132)
2015 (10804)
2014 (7360)
2013 (5766)
2012 (6231)
2011 (6612)
2010 (5695)
Location
Africa (253)
Alabama (7)
Alaska (4)
Arizona (41)
Arkansas (2)
Asia (12468)
Australia (2397)
California (1178)
Canada (369)
China (143)
Colorado (50)
Connecticut (49)
Delaware (35)
Europe (33225)
Florida (165)
Georgia (70)
Idaho (14)
Illinois (141)
India (9)
Indiana (85)
Iowa (2)
Japan (65)
Kansas (29)
Kentucky (7)
Louisiana (5)
Maine (11)
Maryland (213)
Massachusetts (788)
Michigan (38)
Minnesota (83)
Missouri (17)
Montana (6)
Nebraska (6)
Nevada (17)
New Hampshire (10)
New Jersey (431)
New Mexico (7)
New York (461)
North Carolina (172)
Northern California (502)
Ohio (36)
Oklahoma (3)
Oregon (4)
Pennsylvania (286)
Puerto Rico (3)
Rhode Island (4)
South America (375)
South Carolina (7)
Southern California (483)
Tennessee (17)
Texas (145)
Utah (19)
Virginia (26)
Washington D.C. (6)
Washington State (156)
Wisconsin (10)
174,782 Results for "menarini group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
March 20, 2025
·
8 min read
Press Releases
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
January 10, 2025
·
5 min read
Press Releases
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
December 12, 2024
·
10 min read
Pharm Country
Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
The Menarini Group, a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc., a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated results from phase 1b/2 ELECTRA and ELEVATE clinical studies evaluating elacestrant in combination with other treatments.
May 23, 2024
·
9 min read
Business
Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries
Venatorx Pharmaceuticals and Menarini Group today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to commercialize, upon approval of relevant health authorities, cefepime-taniborbactam in 96 countries.
January 9, 2024
·
6 min read
Press Releases
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
December 16, 2024
·
11 min read
Press Releases
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
November 25, 2024
·
11 min read
Business
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU®
The Menarini Group and Stemline Therapeutics, Inc. presented results from phase 1b/2 ELEVATE and ELECTRA clinical studies evaluating ORSERDU® (elacestrant) in combination with other treatments.
December 11, 2023
·
8 min read
Pharm Country
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
The Menarini Group and Stemline Therapeutics, Inc. announced that they have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.
January 4, 2024
·
6 min read
Pharm Country
Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition
The Menarini Group and Stemline Therapeutics, Inc. announced that they will present new data related to ORSERDU® and ELZONRIS® in two upcoming congresses.
November 20, 2023
·
13 min read
1 of 17,479
Next
